Tango

Product Details
Specifications
Accessories
Video Gallery
Documents

Engineered to Outperform. Built to Outlast.

Tango is Engineered to be Faster and More Precise

Industry’s fastest firing rate at 3 shots per second: Proprietary cavity facilitates effective heat transfer and cooling, combined with rapid recharging of the pulse capacitors.
Precise adjustment of parameter settings at 0.1 mJ increments: Automatic calibration process, combined with a series of test-fire sequences, uses feedback from the system’s energy monitor in order to constantly adjust system output.

Tango is Manufactured for More Consistent, Reliable Performance

Lifespan of more than 400,000 shots: YAG optical Q-switch made from thermally matched, homogenous materials to withstand warping and erosion.
Greater shot-to-shot consistency: Custom-built YAG power supply with micro-controller and energy compensation algorithm.

Tango in SLT Mode

Ellex’s proprietary SLT technology features a high level of precision, in which parameter settings can be adjusted at 0.1 mJ increments. This capability, coupled with superior energy control, enables you to deliver highly accurate SLT treatment. All SLT treatment parameters are designed to industry-recognized treatment protocols, maximizing treatment options and ensuring effective patient results.

Offering superior energy control, a sharp-edged aiming beam and the industry’s fastest firing rate at 3 shots per second, Ellex’s proprietary SLT technology allows you to visualize the trabecular meshwork (TM) in greater detail, and to perform procedures faster and with improved accuracy.

Tango’s SLT mode delivers a gentle, non-invasive approach for stimulating the generation of healthy trabecular meshwork cells and managing intraocular pressure without the burn and scar tissue associated with other laser procedures. SLT is a highly effective approach for first-line glaucoma treatments, adjunct therapy with drugs, and alternative therapy when drugs or surgery fail.

Tango in YAG Mode

Tango’s YAG mode features an Ultra Gaussian spot profile and fast rise time which allow you to perform capsulotomies and iridotomies at lower, more efficient energy levels — delivering less energy to the eye. The result is that you can perform capsulotomies with all types of IOLs and with significantly less risk of lens pitting.

Specifications

	SLT Mode	YAG Mode
Laser Source	Q-switched, frequency doubled Nd:YAG	Q-switched Nd:YAG
Wavelength	green: 532 nm	1064 nm
Energy	0.3 to 2.6 mJ, per pulse, continuously variable	0.3 to 10 mJ, per pulse, continuously variable
Pulse Duration	3 ns	4 ns
Burst Mode	single pulse only	1, 2 and 3 pulses per burst, selectable
Spot Size	400 μm	8 μm
Cone Angle	<3 degrees	16 degrees
Posterior Offset	not applicable	± 100 to 500 μm, continuously variable

Common to Both
Repetition Rate	up to 3 hertz
Aiming Beam	red 635 nm, adjustable intensity
Magnification	optimized for enhanced anterior segment visualization
Cooling	air cooled
Electrical Requirements	100-240 VAC, 50/60 Hz, 500 VA
Weight	31 kg, 68 lbs (laser only)
Dimensions (HxWxD)	57 x 75 x 44 cm, 23 x 30 x 18 inches (laser only)
Standard Accessories	Total Solution™ tables, remote display, safety glasses, laser safety sign, dust cover
Optional Accessories	Tonometer mount, SLT laser lens, capsulotomy and iridotomy laser lenses, footswitch, five-position magnification changer, beam splitter, 35 mm camera adapter, video camera adapter, co-observation tube

* Specifications are subject to change without notice.

Accessories

Configured to meet your needs, Tango™ can be combined with the Total Solution™ table range in order to meet the needs of ophthalmic offices, ambulatory surgery centers and hospital outpatient clinics.

Wheelchair Accessible

Wheelchair-Accessible
Easy access for patients in a wheelchair.

Mobile

Portable option for ease of transportation.

Wheelchair Accessible, Mobile

Wheelchair-Accessible-Mobile
Benefits of wheelchair accessibility combined with ease of transportation.

Video Gallery

SLT and the Glaucoma Surgeon – Interview with Tarek Shaarawy, MD (Switzerland)

Not only can SLT achieve sustained IOP reduction for the majority of your glaucoma patients, but it has also been hypothesized to improve the prognosis of glaucoma surgery as compared to long-term medication use.

Predicting Success with SLT – Interview with Cindy L. Huntik, BSc, MD, PhD, FRCS(C) (Canada)

Now that more physicians and patients have access to SLT, it is important to understand how this modality best fits into the management of patients with glaucoma. Since not all patients respond equally to SLT, isolating the factors that can help to determine the likelihood that a patient will respond successfully to treatment with SLT is an important step in glaucoma management.

SLT in the Glaucoma Treatment Armamentarium – Interview with Roberto Cararssa, MD (Italy)

Long-term control of intraocular pressure (IOP) is key to minimizing the ocular damage that eventually occurs in glaucoma patients. The effects of traditional anti-glaucoma eyedrops are short-lived and therefore require diligent, long-term use. Even argon laser trabeculoplasty (ALT), which is known to deliver effective results, starts to lose efficacy within several years. In contrast, selective laser trabeculoplasty (SLT) delivers effective IOP reduction that lasts far longer than any other treatment.

Achieving Versatility in Glaucoma Management – Interview with Shlomo Melamed, MD (Israel)

The effectiveness of SLT in treating open-angle glaucoma and ocular hypertension is well established. SLT can also be used to effectively treat pseudoexfoliation glaucoma, pigmentary glaucoma, normal tension glaucoma, pseudophakic glaucoma, and angle-closure glaucoma post-iridotomy – making it an extremely versatile tool in the glaucoma treatment armamentarium.

The Mechanism of Action of SLT – Interview with K Sheng Lim, MB ChB, MD, FRCOphth (UK)

A number of theories have been proposed regarding the mechanism of action of Selective Laser Trabeculoplasty (SLT). Whilst SLT has been shown to achieve a similar therapeutic effect as Argon Laser Trabeculoplasty (ALT) in the treatment of glaucoma, the mechanical and biological effects differ markedly. Most importantly, SLT is able to achieve the desired therapeutic effect without the coagulative damage caused by ALT. Watch the video interview with Mr. Lim to learn more.

SLT: The Standard of Care for Glaucoma – Interview with Robert Paden, MD (USA)

SLT and the Refractive Surgeon – Interview with Matthias Maus, MD (Germany)

The glaucoma medications used to control the IOP of refractive patients often add to the blurred vision experienced by these patients on a daily basis. This leaves the refractive surgeon with the frustrating task of correcting refractive error without being able to eliminate a key contributor to the problem. In this video interview, Matthias Maus, MD, one of Germany’s leading refractive surgeons, addresses how SLT the role of SLT as an effective first-line glaucoma treatment for these patients, whilst eliminating the need for troublesome medications.

Bringing Down the Cost of Glaucoma Treatment with SLT – Interview with Randy E. Craven, MD (USA)

One of the biggest advantages of SLT is that, in addition to being an effective approach for first-line glaucoma treatment, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, it has also been found to be a more economical approach when compared to topical medications. In this video interview Randy E. Craven, MD, spotlights the many financial benefits of SLT for the patient — and for the wider healthcare system.

SLT Treatment Protocol – Interview with Lawrence F. Jindra, MD (USA)

With one of the world’s largest SLT case studies – more than 4500 eyes treated – Lawrence F. Jindra is considered to be an expert in the use of SLT to treat glaucoma. In this video interview, Dr. Jindra highlights how to achieve the best results when using SLT to treat various types of glaucoma, and on various patient types.

SLT as a Primary Therapy for Glaucoma – Interview with Andrew G. Iwach, MD (USA)

According to glaucoma expert Andrew G. Iwach, MD, at the ASCRS 2013 in San Francisco, he and his colleagues have known for a long time that SLT delivers better IOP-reducing results when used as primary therapy.

SLT as Primary, Adjunct and Alternative Therapy for Glaucoma – Interview with Andrew G. Iwach, MD (USA)

SLT is a highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail.

Documents

Tango Product Brochure Download

Tango

Product Information

Engineered to Outperform. Built to Outlast.

Tango in SLT Mode

Tango in YAG Mode

Specifications

Specifications